{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:35:38Z","timestamp":1779363338225,"version":"3.51.4"},"reference-count":38,"publisher":"Baishideng Publishing Group Inc.","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2008]]},"DOI":"10.3748\/wjg.14.6641","type":"journal-article","created":{"date-parts":[[2008,11,27]],"date-time":"2008-11-27T12:28:15Z","timestamp":1227788895000},"page":"6641","source":"Crossref","is-referenced-by-count":48,"title":["How expensive is inflammatory bowel disease? A critical analysis"],"prefix":"10.3748","volume":"14","author":[{"given":"Selwyn","family":"Odes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6; discussion 16-19.","DOI":"10.3109\/00365528909091339"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, Munkholm P, Bodini P, O'Morain C, Mouzas IA. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 2006;55:510-518.","DOI":"10.1136\/gut.2005.072793"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Hoie O, Schouten LJ, Wolters FL, Solberg IC, Riis L, Mouzas IA, Politi P, Odes S, Langholz E, Vatn M. Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut 2007;56:497-503.","DOI":"10.1136\/gut.2006.101519"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, Harmsen WS, Zinsmeister AR. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117:49-57.","DOI":"10.1016\/S0016-5085(99)70549-4"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Wolters FL, Joling C, Russel MG, Sijbrandij J, De Bruin M, Odes S, Riis L, Munkholm P, Bodini P, Ryan B. Treatment inferred disease severity in Crohn's disease: evidence for a European gradient of disease course. Scand J Gastroenterol 2007;42:333-344.","DOI":"10.1080\/00365520600930750"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Russel MG, Stockbrugger RW. Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol 1996;31:417-427.","DOI":"10.3109\/00365529609006759"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997;32:1134-1139.","DOI":"10.3109\/00365529709002993"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Sculher M. The role and estimation of productivity costs in economic evaluation. Economic evaluation in health care New York: Oxford University Press; 2001;94-112.","DOI":"10.1093\/oso\/9780192631770.003.0005"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992;14:309-317.","DOI":"10.1097\/00004836-199206000-00009"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992;14:318-327.","DOI":"10.1097\/00004836-199206000-00010"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol 2000;95:1955-1960.","DOI":"10.1111\/j.1572-0241.2000.02261.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn's disease. Am J Gastroenterol 2000;95:524-530.","DOI":"10.1111\/j.1572-0241.2000.01779.x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol 2000;95:677-683.","DOI":"10.1111\/j.1572-0241.2000.01845.x"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471-1478.","DOI":"10.1136\/gut.2004.041616"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Ebinger M, Leidl R, Thomas S, Von Tirpitz C, Reinshagen M, Adler G, Konig HH. Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. J Gastroenterol Hepatol 2004;19:192-199.","DOI":"10.1111\/j.1440-1746.2004.03251.x"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Odes S, Vardi H, Friger M, Wolters F, Russel MG, Riis L, Munkholm P, Politi P, Tsianos E, Clofent J. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131:719-728.","DOI":"10.1053\/j.gastro.2006.05.052"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996;31:260-266.","DOI":"10.3109\/00365529609004876"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Juan J, Estiarte R, Colome E, Artes M, Jimenez FJ, Alonso J. Burden of illness of Crohn's disease in Spain. Dig Liver Dis 2003;35:853-861.","DOI":"10.1016\/j.dld.2003.07.002"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther 2006;23:451-463.","DOI":"10.1111\/j.1365-2036.2006.02786.x"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-869.","DOI":"10.1053\/j.gastro.2005.01.048"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2001;120:1640-1656.","DOI":"10.1053\/gast.2001.24884"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Jewell DP, Satsangi J, Lobo A, Probert C, Forbes A, Ghosh S, Shaffer J, Frenz M, Drummond H, Troy G. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005;17:1047-1052.","DOI":"10.1097\/00042737-200510000-00007"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008;28:76-87.","DOI":"10.1111\/j.1365-2036.2008.03709.x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Saro C, da la Coba C, Casado MA, Morales JM, Otero B. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther 2007;26:1313-1323.","DOI":"10.1111\/j.1365-2036.2007.03507.x"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007;26:1509-1520.","DOI":"10.1111\/j.1365-2036.2007.03548.x"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Jaisson-Hot I, Flourie B, Descos L, Colin C. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004;20:274-279.","DOI":"10.1017\/S0266462304001084"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A:5-36.","DOI":"10.1155\/2005\/269076"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Odes S, Vardi H, Friger M, Wolters F, Hoie O, BMoum B, Bernklev T, Yona H, Russel M, Munkholm P. Effect of phenotype on health care costs in Crohn’s disease: A European study using the Montreal classification. J Crohn's Colitis 2007;1:87-96.","DOI":"10.1016\/j.crohns.2007.08.004"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-782.","DOI":"10.1136\/gut.49.6.777"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Aldhous MC, Drummond HE, Anderson N, Smith LA, Arnott ID, Satsangi J. Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am J Gastroenterol 2007;102:577-588.","DOI":"10.1111\/j.1572-0241.2007.01064.x"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Riis L, Vind I, Vermeire S, Wolters F, Katsanos K, Politi P, Freitas J, Mouzas IA, O'Morain C, Ruiz-Ochoa V. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis 2007;13:24-32.","DOI":"10.1002\/ibd.20047"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Odes S, Friger M, Vardi H, Claessens G, Bossuyt X, Riis L, Munkholm P, Wolters F, Yona H, Hoie O. Role of ASCA and the NOD2\/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a project of the European Collaborative Study Group on Inflammatory Bowel Disease. Inflamm Bowel Dis 2007;13:874-881.","DOI":"10.1002\/ibd.20122"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Russell RK, Drummond HE, Nimmo EE, Anderson N, Smith L, Wilson DC, Gillett PM, McGrogan P, Hassan K, Weaver LT. Genotype-phenotype analysis in childhood-onset Crohn's disease: NOD2\/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis 2005;11:955-964.","DOI":"10.1097\/01.MIB.0000183423.38037.f3"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Cruyssen BV, Peeters H, Hoffman IE, Laukens D, Coucke P, Marichal D, Cuvelier C, Remaut E, Veys EM, Mielants H. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clin Exp Immunol 2005;140:354-359.","DOI":"10.1111\/j.1365-2249.2005.02759.x"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004;99:2393-2404.","DOI":"10.1111\/j.1572-0241.2004.40304.x"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Lipscomb J, Weinstein MC, Torrance GW. Time preference. Cost-effectiveness in health and medicine New York: Oxford; 1996;214-246.","DOI":"10.1093\/oso\/9780195108248.003.0007"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis 2007;13:1529-1535.","DOI":"10.1002\/ibd.20250"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-96.","DOI":"10.1046\/j.1572-0241.2003.04010.x"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v14\/i43\/6641.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T12:52:46Z","timestamp":1709470366000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v14\/i43\/6641.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":38,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.14.6641","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}